Revolutionizing the understanding of treatment response to improve patient outcomes
August 20, 2020
On Thursday (8.20.20) AIQ's Chief Innovation Officer, Stephen Yip, Ph.D. delivered a digital address to researchers at the University of Chicago. The presentation centered on the value that AIQ's medical software device platform can bring to clinical studies that focus on the effects of therapy in patients suffering from COVID-19. AIQ is actively working to support COVID-19 research by supplying our treatment response technology to those researching the virus.
August 12, 2020
Due to COVID -19, we have decided to suspend all in person meetings until further notice. We're all anxious to get back on the road soon, to meet with customers, partners and advocates.
Advanced imaging is one technology that could offer a real solution in predicting both the beneficial treatment response and the harmful side effects of immunotherapy treatments. At AIQ Solutions, we are working on technology that combines PET/CT scan data with advanced algorithms to better determine which patients will have a desirable response to immunotherapy.
Delivering actionable intelligence that enhances understanding of treatment response for complex diseaseS
The AIQ Solutions medical software platform allows researchers to understand disease better and clinicians to manage patients more effectively.
Incomplete treatment response information can lead to ineffective therapy choices
Per the US FDA, AIQ technology is indicated for use in the identification, quantification, and evaluation of Regions of Interest (ROIs) from digital medical images, including PET and CT. Any other applications of AIQ technology are for research purposes only.